Sodium-glucose link transporter-2 inhibitors in reduced renal function: cross-class comparison from the Association of British Clinical Diabetologists (ABCD) audits
Crabtree, Thomas Bickerton, Alex Gallagher, Alison Elliott, Jackie Gallen, Ian Dhatariya, Ketan Raghavan, Rajeev Ryder, Robert
Crabtree, Thomas
Bickerton, Alex
Gallagher, Alison
Elliott, Jackie
Gallen, Ian
Dhatariya, Ketan
Raghavan, Rajeev
Ryder, Robert
Citations
Altmetric:
Affiliation
University Hospitals of Derby and Burton NHS Trust; Yeovil District Hospital NHS Trust; Norfolk and Norwich University Hospitals NHS Trust; University Hospitals of Leicester NHS Trust; Sheffield Teaching Hospitals NHS Trust; Sandwell & West Birmingham NHS Trust
Other Contributors
Publication date
2022-09-22
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background and aims: The ABCD sodium-glucose link transporter-2 inhibitor (SGLT2i) audits
launched with the aim of collecting real-world outcome data in UK practice. Previous work from the
individual audits suggests that HbA1c reductions persist at lower eGFR levels but are less than in
those with preserved renal function. The aim of this analysis is to assess HbA1c outcomes at reduced
eGFR levels across the class and to assess for any differences between drugs.
Materials and methods: Data were extracted from the ABCD audits for inclusion; missing data was
multiply imputed. Individuals were grouped by baseline renal function using eGFR (mL/min/1.7m2
)
cut-offs as defined in chronic disease staging as follows: group 1 (eGFR≥90); group 2 (eGFR 60-89);
group 3 (eGFR <60). Analysis was performed using a multiple linear regression model to correct for
change in other covariates with Bonferroni adjustments for between group comparisons.
Results: Data for 21,338 individuals were included (Empagliflozin=11,234; Dapagliflozin=7,841;
Canagliflozin=2,263) with mean±SD age 60.0±10.4years; HbA1c 75.8±2.53mmol/mol; BMI
33.9±7.1kg/m2
; weight 97.5±22.1kg and eGFR 81.6±13.3mL/min/1.73m2
. Median duration of diabetes
8.1 years (IQR 4.2-12.3). 61.2% were male. The median duration of follow-up across the population
was 1.7 years (IQR 0.9-2.8). HbA1c fell by 9.8mmol/mol (95% CI 9.5-10.1, p<0.0001) across the
entire population. Including all levels of renal function, empagliflozin was associated with larger
reductions in HbA1c than dapagliflozin (10.4mmol/mol [95% CI 10.0-10.7] vs. 9.0mmol/mol [95% CI
8.5-9.5]; p-value between drugs <0.0001) but no other differences between SGLT2i drugs were noted.
Group 1 findings mirrored this with HbA1c reduction of 11.4mmol/mol (95% CI 10.9-11.9) with
empagliflozin vs. 9.9mmol/mol (95% CI 9.3-10.5) with dapagliflozin (p <0.0001) and no difference
was noted between any other drug comparisons. In groups 2 and 3 no difference in HbA1c reductions
was noted between drugs. Within each drug group, and across the entire population, there was a trend
towards smaller HbA1c reductions in those in group 2 and 3 but failing to reach statistical significance
(p>0.3 for all).
Conclusion: In those with preserved renal function (eGFR>90) empagliflozin may have greater
glycaemic efficacy than dapagliflozin. No difference in glucose outcomes between the drugs was
noted at lower eGFR levels. Interestingly, in this analysis the difference in HbA1c reductions at with
lower eGFR failed to reach statistical significance but a trend toward attenuated glucose lowering
effects was noted.
Citation
Crabtree Thomas, Bickerton Alex, Gallagher Alison, Elliott Jackie, Gallen Ian, Dhatariya Ketan, Raghavan Rajeev, Ryder Robert. Sodium-glucose link transporter-2 inhibitors in reduced renal function: cross-class comparison from the Association of British Clinical Diabetologists (ABCD) audits. 2022 Sept 22. https://www.easd.org/media-centre/#!resources/sodium-glucose-link-transporter-2-inhibitors-in-reduced-renal-function-cross-class-comparison-from-the-association-of-british-clinical-diabetologists-abcd-audits-4cbac1d3-1fd5-4129-b918-3b20f13ed80b
Type
Article